DNA-encoded library (DEL) screening has become a standard tool in small molecule drug discovery. Yet even as its adoption for hit finding grows, the vast amounts of data it generates is generally overlooked. More than 99 percent of the information produced during a DEL screen is typically neglected in favor of choosing a handful of hits to synthesize and test. That ignored data holds incredible, untapped insight into molecular interactions, SAR trends, mechanisms of action, and potential risks that can radically influence compound progression.

This webinar introduces X-Chem’s approach to chemomics, our framework for unlocking the full power of DEL data. Built on the world’s most powerful and validated DEL platform and enhanced by computational sciences, our chemomic approaches shift how discovery teams approach early-phase decision-making. It transforms raw screening output into structured, decision-ready insight before synthesis even begins.

Explore how chemomics works at X-Chem, why it matters, and how it changes the economics and efficiency of small molecule discovery.

Key Takeaways

• Understand why the majority of DEL data has historically been ignored, and what is being missed
• Learn how X-Chem’s chemomic approaches transform full DEL output into deep SAR, structure–function maps, and early mechanistic insights
• See how front-loaded data improves the understanding of target biology and candidate selection and reduces downstream risk
• Gain a clear picture of how chemomics fits within modern discovery workflows
• Learn how X-Chem combines DEL, computational sciences, and unmatched expertise to help partners launch more informed and successful programs